Intraoperative lymph node staging of prostate cancer: The case against

ANZ Journal of Surgery

Volumn 73, Issue 5, 2003, Pages 263-266

  Garrett, Kerry L ^a   McNeal, John E ^b   Cohen, Ronald J ^c,d  

^a Tissugen Pty Ltd   (Australia)

^b Uropath   (Australia)

^c STANFORD UNIVERSITY   (United States)

^d Uropath Pty Ltd   (Australia)

Author keywords

Lymph node dissection; Prostatectomy; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURGERY; FROZEN SECTION; HEALTH CARE COST; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PROSTATE CANCER; PROSTATECTOMY; SCREENING;

ADULT; AGED; HUMANS; INTRAOPERATIVE CARE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 0038576165     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-2197.2003.t01-1-02612.x     Document Type: Article

References (30)

1. Link RE, Morton RA. Indications for pelvic lymphadenectomy in prostate cancer. Urol. Clin. North Am. 2001; 28: 491-8.
2. Paulson DF. Staging lymphadenectomy should not be an antecedent to treatment in localized prostatic carcinoma. Urology 1985; 25: 7-14.
3. Bishoff JT, Reyes A, Thompson 1M et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 1995; 45: 270-4.
4. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol. 1994; 151: 1315-20.
5. Hoenig DM, Chi S, Porter C et al. Risk of nodal metastases at laparoscopic pelvic lymphadenectomy using PSA, Gleason score, and clinical stage in men with localized prostate cancer. J. Endourol. 1997; 11: 263-5.
6. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79: 528-37.
7. Narayan P, Fournier G, Gajendran V et al. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 1994; 44: 519-24.
8. Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J. Urol. 1987; 138: 92-8.
9. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51.
10. Rogers E, Gurpinar T, Dillioglugil O et al. The role of digital rectal examination, biopsy Gleason sum and prostate-specific antigen in selecting patients who require pelvic lymph node dissections for prostate cancer. Br. J. Urol. 1996; 78: 419-25.
11. Sands ME, Zagars GK, Pollack A, von Eschenbach AC. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology 1994; 44: 215-20.
12. Han M, Snow PB, Brandt JM, Partin AW. Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer 2001; 91: 1661-6.
13. Crawford ED, Batuello JT, Snow P et al. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma. Cancer 2000; 88: 2105-9.
14. Blute ML, Bergstralh EJ, Partin Aw et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J. Urol. 2000; 164: 1591-5.
15. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400.
16. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J. Urol. 2000; 164: 101-5.
17. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol. 1994; 152: 1831-6.
18. Epstein JI. Pathologic assessment of the surgical specimen. Urol. Clin. North Am. 2001; 28: 567-94.
19. Young MP, Kirby RS, O'Donoghue EP, Parkinson MC. Accuracy and cost of intraoperative lymph node frozen sections at radical prostatectomy. J. Clin. Pathol. 1999; 52: 925-7.
20. Edelstein RA, Zietman AL, de las Morenas A et al. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996; 47: 370-5.
21. Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J. Urol. 2000; 163: 1183-8.
22. Slawin KM, Shariat SF, Nguyen C et al. Detection of metastatic prostate cancer using a splice variant-specific reverse transcription-polymerase chain reaction assay for human glandular kallikrein. Cancer Res. 2000; 60: 7142-8.
23. Fujioka T, Koike H, Aoki H, Ohhori T, Chiba R, Okamoto S. Significance of staging pelvic lymphadenectomy for prostatic cancer. Urol. Int. 1987; 42: 380-4.
24. Brossner C, Ringhofer H, Hernady T, Kuber W, Madersbacher S, Pycha A. Lymphatic drainage of prostatic transition and peripheral zones visualized on a three-dimensional workstation. Urology 2001; 57: 389-93.
25. Wawroschek F, Vogt H, Weckermann D, Wagner T, Harzmann R. The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification. Eur. Urol. 1999; 36: 595-600.
26. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J. Urol. 2001; 166: 1715-19.
27. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 1994; 152: 1837-42.
28. Amling CL, Leibovich BC, Lerner SE et al. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin. Urol. Oncol. 1997; 15: 215-21.
29. Oefelein MG, Smith ND, Grayhack JT, Schaeffer AJ, McVary KT. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J. Urol. 1997; 158: 1460-5.
30. van den Ouden D, Schroder FH. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. World J. Urol. 2000; 18: 194-203.